Literature DB >> 10975556

Surgical standards in the management of ovarian cancer.

R E Bristow1.   

Abstract

Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care. Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer. Although randomized trials are lacking, the survival advantage associated with optimal primary cytoreduction has been consistent and reproducible. With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an "optimal" surgical procedure is that which leaves the patient with no visible residual disease. The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease. Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer. Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.

Entities:  

Mesh:

Year:  2000        PMID: 10975556     DOI: 10.1097/00001622-200009000-00015

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  16 in total

1.  MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer.

Authors:  Lufei Wang; Jin He; Hongmei Xu; Longjie Xu; Na Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.

Authors:  Robert L Coleman; Anil K Sood
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

3.  MicroRNA-215 targets NOB1 and inhibits growth and invasion of epithelial ovarian cancer.

Authors:  Yang Lin; Yang Jin; Tianmin Xu; Shunqing Zhou; Manhua Cui
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Vaginal rupture caused by transvaginal ultrasonography in follow-up for ovarian cancer.

Authors:  Lene Lundvall; Flemming Jensen; Henrik Roed; Christian Ottosen; Caroline Ewertsen; Birthe Merete Henriksen
Journal:  BMJ Case Rep       Date:  2009-08-13

5.  MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.

Authors:  Yanli Wang; Chunling Xu; Yun Wang; Xiaomeng Zhang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.

Authors:  M Takakura; M Nakamura; S Kyo; M Hashimoto; N Mori; T Ikoma; Y Mizumoto; T Fujiwara; Y Urata; M Inoue
Journal:  Cancer Gene Ther       Date:  2010-01       Impact factor: 5.987

7.  The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Authors:  Mani Nassir; Jun Guan; Hrvoje Luketina; Timo Siepmann; Irena Rohr; Rolf Richter; Dan Cacsire Castillo-Tong; Robert Zeillinger; Ignace Vergote; Els Van Nieuwenhuysen; Nicole Concin; Christian Marth; Christina Hall; Sven Mahner; Linn Woelber; Jalid Sehouli; Elena Ioana Braicu
Journal:  Tumour Biol       Date:  2015-09-29

8.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14

9.  Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.

Authors:  Farr R Nezhat; Shaghayegh M Denoble; Jennifer E Cho; Douglas N Brown; Enrique Soto; Linus Chuang; Herbert Gretz; Prakash Saharia
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

10.  Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?

Authors:  C Fotopoulou; K Savvatis; P Kosian; I E Braicu; G Papanikolaou; K Pietzner; S-C Schmidt; J Sehouli
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.